With Merck patient studies in doubt, 2 analysts downgrade drugmaker’s rating
On Friday, the Whitehouse Station-based company announced it will delay application of a new type of osteoporosis drug to review safety data from one study and look at longer-term data from an extension study
The rest is here:
With Merck patient studies in doubt, 2 analysts downgrade drugmaker’s rating
Leave a Reply
You must be logged in to post a comment.
View video inside